JPS6237612B2 - - Google Patents
Info
- Publication number
- JPS6237612B2 JPS6237612B2 JP56086147A JP8614781A JPS6237612B2 JP S6237612 B2 JPS6237612 B2 JP S6237612B2 JP 56086147 A JP56086147 A JP 56086147A JP 8614781 A JP8614781 A JP 8614781A JP S6237612 B2 JPS6237612 B2 JP S6237612B2
- Authority
- JP
- Japan
- Prior art keywords
- protease
- type
- allergic diseases
- acidic
- asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000026935 allergic disease Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 10
- 108091005508 Acid proteases Proteins 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000002485 urinary effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 description 16
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 14
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 14
- 208000006673 asthma Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940092253 ovalbumin Drugs 0.000 description 7
- 230000007815 allergy Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000006215 rectal suppository Substances 0.000 description 2
- 229940100618 rectal suppository Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56086147A JPS57206623A (en) | 1981-06-04 | 1981-06-04 | Remedy for allergic disease |
| CA000395742A CA1181005A (en) | 1981-02-10 | 1982-02-08 | Therapeutic agent for treatment of allergic diseases, immune complex diseases and tumors |
| GB8203682A GB2095993B (en) | 1981-02-10 | 1982-02-09 | Compositions containing human urinary acid protease |
| SE8200748A SE455163B (sv) | 1981-02-10 | 1982-02-09 | Uropepsin for anvendning som terapeutikum mot allergiska sjukdomar, immunkomplexsjukdomar och tumorer |
| AU80290/82A AU531314B2 (en) | 1981-02-10 | 1982-02-09 | Therapeutic agent containing human urinary acid protease |
| CH782/82A CH653557A5 (de) | 1981-02-10 | 1982-02-09 | Zur behandlung von allergischen zustaenden, immunkomplexkrankheiten und tumoren geeignetes therapeutisches mittel. |
| NL8200509A NL8200509A (nl) | 1981-02-10 | 1982-02-10 | Geneesmiddel voor allergiekwalen, immuuncomplexziekten en tumoren; werkwijze voor het behandelen van patienten die hieraan lijden. |
| IT47761/82A IT1154280B (it) | 1981-02-10 | 1982-02-10 | Agente terapeutico a base di protea si acida e suo impiego in pazienti affetti da disordini allergici,malattie da immuno-complessi e tumori |
| FR8202145A FR2499409A1 (fr) | 1981-02-10 | 1982-02-10 | Agent therapeutique a base d'une protease acide, pour le traitement des troubles allergiques, des maladies avec immunocomplexe et des tumeurs |
| EP82100973A EP0059346B1 (en) | 1981-02-10 | 1982-02-10 | Therapeutic agent containing a human urinary pepsin |
| DE19823204631 DE3204631A1 (de) | 1981-02-10 | 1982-02-10 | Therapeutisches mittel und dessen verwendung |
| DE8282100973T DE3273953D1 (en) | 1981-02-10 | 1982-02-10 | Therapeutic agent containing a human urinary pepsin |
| US06/365,465 US4540569A (en) | 1981-02-10 | 1982-04-05 | Method for treatment of allergic disorders and immune complex diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56086147A JPS57206623A (en) | 1981-06-04 | 1981-06-04 | Remedy for allergic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57206623A JPS57206623A (en) | 1982-12-18 |
| JPS6237612B2 true JPS6237612B2 ( ) | 1987-08-13 |
Family
ID=13878617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56086147A Granted JPS57206623A (en) | 1981-02-10 | 1981-06-04 | Remedy for allergic disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57206623A ( ) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6239012U ( ) * | 1985-08-29 | 1987-03-09 | ||
| JPH0594521U (ja) * | 1992-05-25 | 1993-12-24 | 光洋精工株式会社 | 止め輪 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2711436B2 (ja) * | 1995-02-22 | 1998-02-10 | マルホ株式会社 | アレルギー治療剤及びアレルギー対応食品 |
-
1981
- 1981-06-04 JP JP56086147A patent/JPS57206623A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6239012U ( ) * | 1985-08-29 | 1987-03-09 | ||
| JPH0594521U (ja) * | 1992-05-25 | 1993-12-24 | 光洋精工株式会社 | 止め輪 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57206623A (en) | 1982-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4335099A (en) | Employment of enteric coated IgA for hypoproteinemia in intestinal infectious diseases | |
| AU735950B2 (en) | A drug preparation for oral administration | |
| EP0059346B1 (en) | Therapeutic agent containing a human urinary pepsin | |
| JPS6237612B2 ( ) | ||
| EP0758656B1 (en) | Immunoglobulin activated by mixing with a histamine component | |
| EP0100366A1 (en) | Agent for treating allergic disease, immunity complex disease, and tumour | |
| Taylor et al. | Recurrent pseudo‐scarlatina and allergy to pseudoephedrine hydrochloride | |
| US4120950A (en) | Medicament for preventing and treating pseudomonas aeruginosa infections and method of its preparation | |
| US4591504A (en) | Human leucocyte pepsin-like enzyme as a therapeutic agent for treating allergic disorders and immune complex diseases | |
| US4534966A (en) | Composition for treating infectious diseases, gout or arteriosclerosis containing human pepsin and/or human leukocyte pepsin-like enzyme and method for using same | |
| EMMETT | Refractory amebic abscess of the liver treated with chloroquine | |
| JPS6237613B2 ( ) | ||
| JP3477717B2 (ja) | 川崎病予防薬および急性期症状治療薬 | |
| US5939072A (en) | Herbal composition and method of treating viral infection of the liver | |
| JP2547325B2 (ja) | アレルギ−性疾患治療用外用剤 | |
| JPS6355494B2 ( ) | ||
| JPH04971B2 ( ) | ||
| Kitamura | The Department of the Internal Medicine and the Physical Therapy, University of Tokyo Director: Prof. Yoshio Oshima) Infiuences of the anabolic steroids on the production of antibodies and allergic responses in animals were studied and following results were obtained. l. Rabbit were sensitized with egg-albumin and treated simultaneously with various anabolic steroids | |
| JPS6237611B2 ( ) | ||
| Butler Jr et al. | Biologic effects of specific antibodies in reversing the pharmacologic and toxic effects of digoxin | |
| JPS62205033A (ja) | 関節リウマチ治療剤 | |
| JPH05163158A (ja) | 人尿性キニノゲナーゼを有効成分とする皮膚潰瘍の予防及び治療剤 | |
| JPH0585531B2 ( ) | ||
| JPH0361655B2 ( ) | ||
| JPS63241358A (ja) | 肺微小循環部位における損傷の診断法 |